NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT03625037 2026-03-03
EPCOREâ„¢ NHL-1
Genmab
Phase 1/2 Active not recruiting
NCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT02048813 2025-11-28
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT02500407 2025-09-12
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1/2 Completed
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT02004522 2023-09-21
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
SecuraBio
Phase 3 Completed
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated